All In Biotech

Drug Trial Radar · NCT00467259

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder.

Last checked: Nov 19, 2026Latest source record: Dec 15, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,271 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,271

Actual

Start

Apr 2007

Primary completion

Jan 2009

Study completion Jan 2009

Sponsor

Lead sponsor
Warner ChilcottIndustry
Sponsor type
Industry
First posted
Apr 30, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 45 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.

Conditions

  • Hypoactive Sexual Desire Disorder

Interventions

  • Testosterone Transdermal SystemDrug

    Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks

  • Placebo patchDrug

    placebo patch, changed twice a week for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1Time frame: 52 weeks

Locations

115 sites in 1 country. Site status is shown where the registry gives one.

  • Study Facility

    Birmingham, Alabama

  • Research Facility

    Birmingham, Alabama

  • Research Facility

    Mobile, Alabama

  • Research Facility

    Montgomery, Alabama

  • Test Facility

    Chandler, Arizona

  • Study Facility

    Peoria, Arizona

  • Research Facility

    Phoenix, Arizona

  • Research Facility

    Phoenix, Arizona

  • Research Facility

    Scottsdale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Facility

    Tucson, Arizona

  • Study Facility

    Tuscon, Arizona

  • Site Facility

    Jonesboro, Arkansas

  • Site Facility

    Little Rock, Arkansas

  • Research Facility

    Anaheim, California

  • Research Site

    Berkeley, California

  • Research Facility

    Palm Desert, California

  • Research Facility

    Pasadena, California

  • Research Facility

    San Diego, California

  • Research Facility

    San Ramon, California

  • Test Facility

    Santa Rosa, California

  • Site Facility

    Upland, California

  • Research Facility

    Vista, California

  • Site Facility

    Vista, California

  • Site Facility

    Westlake Village, California

  • Test Facility

    Denver, Colorado

  • Research Facility

    Longmont, Colorado

  • Test Facility

    New London, Connecticut

  • Study Facility

    Waterbury, Connecticut

  • Research Facility

    Washington D.C., District of Columbia

  • Research Facility

    Boynton Beach, Florida

  • Site Facility

    Clearwater, Florida

  • Site Facility

    Daytona Beach, Florida

  • Research Facility

    Gainesville, Florida

  • Research Site

    Jacksonville, Florida

  • Site Facility

    Jupiter, Florida

  • Test Facility

    Miami, Florida

  • Research Facility

    Pinellas Park, Florida

  • Research Facility

    Plantation, Florida

  • Study Facility

    South Miami, Florida

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.